<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060783</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-894</org_study_id>
    <nct_id>NCT05060783</nct_id>
  </id_info>
  <brief_title>Renal Cancer Detection by Plasma/Urine Glycosaminoglycan GAG Score</brief_title>
  <acronym>GaGnostic</acronym>
  <official_title>Renal Cancer Detection by Plasma/Urine Glycosaminoglycan GAG Score</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elypta</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC&#xD;
      compared to healthy samples. In addition, GAG scores correlated with progression-free&#xD;
      survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC&#xD;
      and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs&#xD;
      are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as&#xD;
      angiomyolipomas, oncocytomas, or PEComa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the optimal GAG score</measure>
    <time_frame>2 years</time_frame>
    <description>To identify the optimal GAG score in RCC patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the optimal GAG score</measure>
    <time_frame>2 years</time_frame>
    <description>To identify the optimal GAG score in oncocytoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the optimal GAG score</measure>
    <time_frame>2 years</time_frame>
    <description>To identify the optimal GAG score in healthy individuel</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Renal Cancer</condition>
  <condition>Oncocytoma</condition>
  <arm_group>
    <arm_group_label>Renal Call Carcinoma</arm_group_label>
    <description>Patrients with renal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncocytoma</arm_group_label>
    <description>Patients with oncocytoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy persons</arm_group_label>
    <description>Patients with CT scan shows no renal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GaGnostic</intervention_name>
    <description>Plasma</description>
    <arm_group_label>Healthy persons</arm_group_label>
    <arm_group_label>Oncocytoma</arm_group_label>
    <arm_group_label>Renal Call Carcinoma</arm_group_label>
    <other_name>Glycosaminoglycan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GaGnostic</intervention_name>
    <description>Serum</description>
    <arm_group_label>Healthy persons</arm_group_label>
    <arm_group_label>Oncocytoma</arm_group_label>
    <arm_group_label>Renal Call Carcinoma</arm_group_label>
    <other_name>Glycosaminoglycan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GaGnostic</intervention_name>
    <description>Urine</description>
    <arm_group_label>Healthy persons</arm_group_label>
    <arm_group_label>Oncocytoma</arm_group_label>
    <arm_group_label>Renal Call Carcinoma</arm_group_label>
    <other_name>Glycosaminoglycan</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, Serum and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients referred to our department by family doctors or the primary sector with a&#xD;
        suspicion of renal tumor by CT-scanning will be asked to participate in the study. Patients&#xD;
        with suspected small renal tumor will be offered renal tumor biopsies as standard&#xD;
        procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no&#xD;
             sign of renal cancer.&#xD;
&#xD;
          2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor&#xD;
             (Biopsy or surgical specimen)&#xD;
&#xD;
          3. Sign up information consent&#xD;
&#xD;
          4. Can perform protocol procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-clear cell Renal cell carcinoma&#xD;
&#xD;
          2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney&#xD;
&#xD;
          3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep&#xD;
             vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in&#xD;
             conjunction with primary surgery or postoperatively â‰¤4 weeks will be allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nessn H. Azawi, M.D.</last_name>
      <phone>004526393034</phone>
      <email>nesa@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Nessn Azawi, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Nessn Azawi</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Adenoma, Oxyphilic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

